Lucid Capital upgraded INmune Bio to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company's CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune's pipeline for the upgrade.
